These authors contributed equally to the paper.
Application of an ex vivo cellular model of circadian variation for bipolar disorder research: a proof of concept study
Article first published online: 20 JUN 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 15, Issue 6, pages 694–700, September 2013
How to Cite
Application of an ex vivo cellular model of circadian variation for bipolar disorder research: a proof of concept study. Bipolar Disord 2013: 15: 694–700. © 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd., , , , , , , .
- Issue published online: 3 SEP 2013
- Article first published online: 20 JUN 2013
- Manuscript Accepted: 29 MAR 2013
- Manuscript Received: 22 JUL 2012
- National Institutes of Health. Grant Numbers: MH081003-05, MH63480, D43 TW008302
- Clinical and Translational Pilot Project
- Rockefeller University. Grant Numbers: 5UL1 RR024143-04, P01 AG020677-06A1
- bipolar disorder;
- BmalI ;
Disruption of circadian function has been observed in several human disorders, including bipolar disorder (BD). Research into these disorders can be facilitated by human cellular models that evaluate external factors (zeitgebers) that impact circadian pacemaker activity. Incorporating a firefly luciferase reporter system into human fibroblasts provides a facile, bioluminescent readout that estimates circadian phase, while leaving the cells intact. We evaluated whether this system can be adapted to clinical BD research and whether it can incorporate zeitgeber challenge paradigms.
Fibroblasts from patients with bipolar I disorder (BD-I) (n = 13) and controls (n = 12) were infected ex vivo with a lentiviral reporter incorporating the promoter sequences for Bmal1, a circadian gene to drive expression of the firefly luciferase gene. Following synchronization, the bioluminescence was used to estimate period length. Phase response curves (PRCs) were also generated following forskolin challenge and the phase response patterns were characterized.
Period length and PRCs could be estimated reliably from the constructs. There were no significant case-control differences in period length, with a nonsignificant trend for differences in PRCs following the phase-setting experiments.
An ex vivo cellular fibroblast-based model can be used to investigate circadian function in BD-I. It can be generated from specific individuals and this could usefully complement ongoing circadian clinical research.